The ink dries on the blank cheque craze
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
A year of two halves for US approvals
FDA green lights picked up in the second half, but for the really impressive number look at year-five sales.
Precision pays off for Prometheus
Strong mid-stage data defy doubts following rival Pfizer’s spin off.
GSK deals cell therapy another setback
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
Spero proves a canny dealmaker – again
The developer has now struck two rich deals for the antibiotics space, a field that infrequently sees big sums change hands.
Kymera’s pain could be Priovant’s gain
Pfizer’s Irak-4 inhibitor PF-06650833 definitely, definitely doesn’t work in hidradenitis suppurativa, but there’s at least partly better news for Priovant.
Newamsterdam braves the Spac track
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.